ERRATA


Dr Gupta has received research grant support from The National Institutes of Health (NIH) (R21 ID# AI135705, R01 ID# AI130348), Allergy and Asthma Network, Food Allergy Research & Education, p Inc, Stanford Sean N. Parker Center for Allergy Research, Northwestern University Clinical and Translational Sciences Institute (NUCATS), Aimmune Therapeutics, UnitedHealth Group, Mylan, Thermo Fisher Scientific, and the National Confectioners Association (NCA); and has served as a medical consultant/advisor for Aimmune Therapeutics, Pfizer, Before Brands, Mylan, Kaléo, and DBV Technologies.

Dr Nadeau has received funding, is currently funded by, or has cofounded the following: National Institutes of Health (NIH), Food Allergy Research & Education (FARE), End Allergies Together (EAT), Before Brands, Alladapt Immunotherapeutics, Adare Pharmaceuticals, AstraZeneca, Novartis, Genentech, Astellas, DBV Technologies, ForTra, Aimmune Therapeutics, Regeneron, Sanofi, Nestle, and the Environmental Protection Agency (EPA).

doi:10.1542/peds.2018-3835
*Pediatrics* 2019;143;
DOI: 10.1542/peds.2018-3835 originally published online February 28, 2019;